共 640 条
[41]
Tefferi A(2012)Complete response after imatinib mesylate therapy in a patient with well-differentiated systemic mastocytosis J Clin Oncol 30 e126-2060
[42]
Arock M(2008)Treatment responses to cladribine and dasatinib in rapidly progressing aggressive mastocytosis Eur J Clin Investig 38 869-1720
[43]
Sotlar K(2008)Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis Clin Cancer Res 14 3906-472
[44]
Akin C(2015)Nilotinib in patients with systemic mastocytosis: analysis of the phase 2, open-label, single-arm nilotinib registration study Journal of Cancer Research and Clinical Oncology 141 2047-2541
[45]
Broesby-Olsen S(2009)Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells Clin Exp Allergy 39 1711-641
[46]
Hoermann G(2015)Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth Leukemia 30 464-2401
[47]
Escribano L(2016)Efficacy and safety of midostaurin in advanced systemic mastocytosis N Engl J Med 374 2530-2606
[48]
Fritsche-Polanz Robert(2003)Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria Leukemia Research 27 635-145
[49]
Jordan John-Hendrik(2013)International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis Blood 121 2393-797
[50]
Feix Alexandra(2016)Midostaurin in Advanced Systemic Mastocytosis New England Journal of Medicine 374 2605-1131